RTMS for Refractory Auditory Hallucinations Based on Personalized Targets Using Magnetoencephalography
Shanghai Mental Health Center
36 participants
Feb 5, 2025
INTERVENTIONAL
Conditions
Summary
This study is an before-after study in the same patient, which enrolled 36 psychiatric patients with refractory auditory hallucinations. The target of patient intervention relies on the results of magnetoencephalography localization. The medication and dosage remain unchanged during the intervention period. The investigators assume that the intervention targets for each auditory hallucination patient are individualized.
Eligibility
Inclusion Criteria5
- Clinical diagnosis of schizophrenia
- Must be able to right-handed
- Primary school education or above
- Understand and sign a written informed consent form (jointly signed by the guardian and the participant if under 18 years old)
- Existence of persistent auditory hallucinations (defined as: taking sufficient antipsychotic medication for at least 6 months, combined with 3 antipsychotic medications still ineffective, and no significant improvement in auditory hallucinations symptoms, with an AHRS score still\>12)
Exclusion Criteria6
- MECT treatment within the past 3 months
- Major physical illnesses (organic lesions such as sensory and motor disorders, neurological disorders, and traumatic brain injury)
- Taboo symptoms for rTMS treatment (such as intracranial metal implants)
- Aggressive behavior and an impulse to damage equipment
- Metal (including orthodontic treatment, dental implants) and tattoos inside the body
- Claustrophobia
Interventions
RTMS using pseudo stimulus intervention in weeks 1-2, for a total of 10 days. After resting for 2 weeks, enter the 3-4 weeks of real stimulation, with 5 days of intervention per week for a total of 10 days. Application of rTMS for 1Hz low-frequency intervention, with intervention parameters of 1400 sessions, 100% exercise threshold, and a total of 23 minutes per session. After each target intervention, rest for half an hour to one hour.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06802939